Your browser doesn't support javascript.
loading
A genetic-epigenetic interplay at 1q21.1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis.
Pahlevan Kakhki, Majid; Giordano, Antonino; Starvaggi Cucuzza, Chiara; Venkata S Badam, Tejaswi; Samudyata, Samudyata; Lemée, Marianne Victoria; Stridh, Pernilla; Gkogka, Asimenia; Shchetynsky, Klementy; Harroud, Adil; Gyllenberg, Alexandra; Liu, Yun; Boddul, Sanjaykumar; James, Tojo; Sorosina, Melissa; Filippi, Massimo; Esposito, Federica; Wermeling, Fredrik; Gustafsson, Mika; Casaccia, Patrizia; Hillert, Jan; Olsson, Tomas; Kockum, Ingrid; Sellgren, Carl M; Golzio, Christelle; Kular, Lara; Jagodic, Maja.
Afiliación
  • Pahlevan Kakhki M; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Giordano A; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Starvaggi Cucuzza C; Neurology and Neurorehabilitation Units, IRCCS San Raffaele Hospital, Milan, Italy.
  • Venkata S Badam T; Laboratory of Human Genetics of Neurological Disorders, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Samudyata S; Università Vita-Salute San Raffaele, Milan, Italy.
  • Lemée MV; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Stridh P; Center for Neurology, Academic Specialist Center, Stockholm, Sweden.
  • Gkogka A; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Shchetynsky K; Department of Bioinformatics, Institute for Physics chemistry and Biology (IFM), Linköping university, Linköping, Sweden.
  • Harroud A; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Gyllenberg A; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
  • Liu Y; Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.
  • Boddul S; Institut National de la Santé et de la Recherche Médicale, U1258, Illkirch, France.
  • James T; Université de Strasbourg, Strasbourg, France.
  • Sorosina M; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Filippi M; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Esposito F; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Wermeling F; The Neuro (Montreal Neurological Institute-Hospital), Montréal, QC, Canada.
  • Gustafsson M; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.
  • Casaccia P; Department of Human Genetics, McGill University, Montréal, QC, Canada.
  • Hillert J; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Olsson T; MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences and Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
  • Kockum I; Department of Medicine, Solna, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Sellgren CM; Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Golzio C; Laboratory of Human Genetics of Neurological Disorders, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Kular L; Neurology and Neurorehabilitation Units, IRCCS San Raffaele Hospital, Milan, Italy.
  • Jagodic M; Università Vita-Salute San Raffaele, Milan, Italy.
Nat Commun ; 15(1): 6419, 2024 Jul 30.
Article en En | MEDLINE | ID: mdl-39079955
ABSTRACT
Multiple Sclerosis (MS) is a heterogeneous inflammatory and neurodegenerative disease with an unpredictable course towards progressive disability. Treating progressive MS is challenging due to limited insights into the underlying mechanisms. We examined the molecular changes associated with primary progressive MS (PPMS) using a cross-tissue (blood and post-mortem brain) and multilayered data (genetic, epigenetic, transcriptomic) from independent cohorts. In PPMS, we found hypermethylation of the 1q21.1 locus, controlled by PPMS-specific genetic variations and influencing the expression of proximal genes (CHD1L, PRKAB2) in the brain. Evidence from reporter assay and CRISPR/dCas9 experiments supports a causal link between methylation and expression and correlation network analysis further implicates these genes in PPMS brain processes. Knock-down of CHD1L in human iPSC-derived neurons and knock-out of chd1l in zebrafish led to developmental and functional deficits of neurons. Thus, several lines of evidence suggest a distinct genetic-epigenetic-transcriptional interplay in the 1q21.1 locus potentially contributing to PPMS pathogenesis.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 1 / Pez Cebra / Encéfalo / Metilación de ADN / Epigénesis Genética / Proteínas de Unión al ADN Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 1 / Pez Cebra / Encéfalo / Metilación de ADN / Epigénesis Genética / Proteínas de Unión al ADN Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia